NikoleV Posted September 26, 2012 Share Posted September 26, 2012 Molecular Targets in Lung Cancer: Not Just for Adenocarcinomas Anymore September 25th, 2012 - by Dr. Jack West http://blog.lungevity.org/2012/09/25/mo ... s-anymore/ Dr. Neal’s last topic in his ASCO 2012 Lung Cancer Highlights summary covered a couple of presentations on molecular targets for squamous NSCLC. Long overlooked as focus has turned to adenocarcinomas or other non-squamous subtypes more and more, squamous NSCLC has largely been defined over the past few years by all of the things not appropriate for it: Avastin (bevacizumab) due to excessive bleeding risk, Alimta (pemetrexed) because of a lack of activity, molecular testing for an EGFR mutation or ALK rearrangement due to a low probability of a positive result. But here Dr. Neal reviews emerging research that suggests that there are indeed potentially treatable molecular targets in squamous NSCLC, and that this work should lead to many new trials and therapeutic options for this subset of patients in the coming years. Below you’ll find both the video and audio podcasts for this short program, along with the transcript and figures. Click on the link above to view the video and audio links. Dr. Neal LC Highlights ASCO 2012 Molec Targets Squamous NSCLC Video Transcript Dr. Neal LC Highlights ASCO 2012 Molec Targets Squamous NSCLC Audio Transcript Dr. Neal LC Highlights ASCO 2012 Molec Targets Squamous NSCLC Transcript Dr. Neal LC Highlights ASCO 2012 Molec Targets Squamous NSCLC Figs Very soon I’ll have the question and answer program that will complete this series from the ASCO Highlights webinar. I hope it’s been helpful and interesting. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.